1.A case of pulmonary siderosis confirmed by bronchoalveolar lavage and transbronchial lung biopsy.
Eun A KIM ; Byoung Uk BANG ; Lucia KIM ; Jeon Seon RYU ; Seung Min KWAK ; Hong Lyeol LEE ; Jae Hwa CHO
Tuberculosis and Respiratory Diseases 2004;57(5):476-479
Pulmonary siderosis is one kind of pneumoconiosis, occurs from chronic inhalation of iron or iron oxide. Inhaled iron dust is deposited in the intra-alveolar spaces, which leads to radiological changes and respiratory symptoms. It is diagnosed by iron exposure history, radiological changes, and the evidence of intra-alveolar iron deposit. We have experienced a case of pulmonary siderosis which was confirmed by bronchoalveolar lavage and transbronchial lung biopsy, so report it with a review of literature.
Biopsy*
;
Bronchoalveolar Lavage*
;
Dust
;
Inhalation
;
Iron
;
Lung*
;
Pneumoconiosis
;
Siderosis*
2.Efficacy of Itraconazole Melt-Extrusion Tablet One-week Therapy in Treatment of Hyperkeratotic Type of Tinea Pedis and/or Tinea Manus.
Kee Chan MOON ; Jai Kyoung KOH ; Baik Kee CHO ; Hyung Ok KIM ; Gun Su PARK ; Dae Gyu BYUN ; Jin Woo KIM ; In Kang JANG ; Jong Yuk YI ; Jae Bok JUN ; Tae Jin YOON ; Nack In KIM ; Kyu Suk LEE ; Chill Hwan OH ; Soo Nam KIM ; Sook Ja SON ; Yong Woo CHIN ; Dong Seok KIM ; Gwang Yeol JOE ; Won Woo LEE ; Kyung Sool KWON ; Dae Hun SUH ; Sang Eun MOON ; See Yong PARK ; Kea Jeung KIM ; Jong Suk LEE ; Eun So LEE ; Hyun Joo CHOI ; Eung Ho CHOI ; Ki Hong KIM ; Seung Hoon CHA ; Young Gull KIM ; Jung Hee HAHM ; Hae Young CHOI ; Sung Uk PARK ; Bang Soon KIM ; Sang Wahn KOO ; Byung Soo KIM ; Young Ho WON ; Han Uk KIM ; Eun Sup SONG ; Byoung Soo CHUNG ; Byung In RO ; Chang Kwun HONG ; Jagn Kue PARK ; Tae Young YOUN ; Hee Sung KIM ; Cheol Heon LEE ; Kwang Joong KIM ; Dae Won KOO ; Jong Min KIM ; Chang Woo LEE ; Hee Joon YU
Korean Journal of Dermatology 1999;37(8):1047-1056
BACKGROUND: Since the bioavailability of itraconazole capsule is influenced by patients gastric acidity, it results in treatment failure due to its low dissolution and subsequent low absorption when administered in fasting. Itraconazole Melt-Extrusion tablet has been lately developed in order to improve its dissolution profile. It is the first clinical study to evaluate the efficacy and safety of itraconazole Melt-Extrusion tablet in Korea. OBJECTIVE: This study was conducted to evaluate the efficacy and safety of itraconazole melt-extrusion tablet 400mg daily for 1 week(pulse therapy) for hyperkeratotic type of tinea pedis and manus. METHODS: A clinical and mycological investigation was made of 812 outpatients with hyperkeratotic type of tinea pedis and/or tinea manus who had visited at 52 general hospitals under the lead of the Korean Dermatological Association from June to December, 1998. Patients confirmed by clinically and microscopically as hyperkeratotic type of tinea pedis and/or tinea manus were administered 2 tablets twice a day for one week and followed up for 8 weeks from the start of the medication. RESULTS: The results were summarized as follows; 1. Clinical symptoms of hyperkeratotic type of tinea pedis and/or tinea mauns were significantly improved at the end of study, week 8(p<0.001). 2. Clinical response rate, defined as more than 50% decrease of the sum of the clinical symptom scores, was 79.3%(512/646). 3. Mycological cure rate, dafined as both culture and KOH negative at week 8, was 78.2%(244 /312). 4. 40(5.5%) patients, of the 727 patients evaluable for drug safety evaluation, were reported to have adverse event. CONCLUSION: Itraconazole Melt-Extrusion tablet 400mg/day for 1 week (pulse therapy) is effective and safe in the treatment of hyperkeratotic type of tinea pedis and/or tinea manus.
Absorption
;
Biological Availability
;
Fasting
;
Gastric Acid
;
Hospitals, General
;
Humans
;
Itraconazole*
;
Korea
;
Outpatients
;
Tablets
;
Tinea Pedis*
;
Tinea*
;
Treatment Failure
3.Assessment of Quality of Life in Patient with Toenail Onychomycosis in Korea.
Baik Kee CHO ; Jong Gap PARK ; Hyung OK KIM ; Sung Wook KIM ; Seung Chul BAEK ; Jin Wou KIM ; Si Yong KIM ; Kyu Joong AHN ; Jae Bok JUN ; Chee Won OH ; Nack In KIM ; Kyu Suk LEE ; Chil Hwan OH ; Soo Nam KIM ; Sang Tae KIM ; Sook Ja SON ; Yong Woo CHINN ; Dong Seok KIM ; Won Woo LEE ; Kyung Sool KWON ; Dae Hun SUH ; Kyu Uang WHANG ; Jong Suk LEE ; Jai Kyoung KOH ; Won Hyoung KANG ; Kee Yang CHUNG ; Eung Ho CHOI ; Ki Hong KIM ; Seok Don PARK ; Seung Joo KANG ; Jeong Hee HAHM ; Ki Bum MYUNG ; Bang Soon KIM ; Sang Wahn KOO ; Byung Su KIM ; Young Ho WON ; Han Uk KIM ; Eun Sup SONG ; Byoung Soo CHUNG ; Chang Kwun HONG ; Byung In RO ; Jang Kyu PARK ; Jee Yoon HAN ; Kwang Joong KIM ; Dae Won KOO ; Jong Min KIM ; Jae Hong KIM ; Hee Joon YU ; Kyung Mee YANG
Korean Journal of Medical Mycology 1998;3(2):115-124
BACKGROUND: Onychomycosis, especially toenail onychomycosis has become one of the common fungal infection and has historically been regarded as a cosmetic rather than medical problem by many patients, even by physicians. Recently, however, there are several reports that this is a refractory disease which may cause a deleterious effect on patients' quality of life (QOL). OBJECTIVE: The purpose of this study was to investigate the impact of toenail onychomycosis on QOL in Korea and to assess the changes of QOL after treatment. METHODS: Total 1004 patients with toenail onychomycosis which was confirmed by clinical findings and KOH preparation were enrolled at 47 dermatologic centers in Korea, and interviewed with standardized QOL questionnaire before and after systemic antifungal treatment. Responses to the questionnaire were scored by f-point scale (0~4) and averaged, and were analyzed for 5 dimensions of emotional impact, social impact, symptom and functional impact, patients' views concerning treatment, and relationship with doctor. RESULTS: 1. Before and after treatment, the most serious impact was emotional dimension showing 1.90 and 1.30 in average score (AS), and social (AS: 1.14 and 0.83) and symptom and functional impact (AS: 1.05 and 0.92) was also affected. 2. In female rather than male, statistically more significant impact on patients' QOL was observed in all dimensions. 3. After treatment, 3 of 5 dimensions were improved significantly - emotional dimension (AS: from 1.90 to 1.30), social dimension (AS: from 1.14 to 0.83), patients' view concerning treatment(AS: from 1.34 to 1.02) 4. The degree of patients' satisfaction at the therapeutic effect was very high - 62.4% (immediately after. treatment) and 65.8% (9 months after initiation of treatment) of patients answered excellent or good. CONCLUSION: This study confirms that toenail onychomycosis has significant Impact on the overall QOL of patients. Also the effect of antifungal therapy on patients' QOL were satisfactory. Therefore, both doctor and patient should pay more attention to the treatment of onychomycosis.
Female
;
Humans
;
Korea*
;
Male
;
Nails*
;
Onychomycosis*
;
Quality of Life*
;
Social Change
;
Surveys and Questionnaires